Why do current treatment guidelines lack evidence-based recommendations for psychotic depression pharmacotherapy?

clinical neuroscience resolved
Open a bounty challenge Fund this gap and accept submissions. SPEC-033.
Composite
—
Novelty
—
Mechanistic
—
Druggability
—
Priority
76%
Importance
85%
Tractability
70%
Market price
50%

Description

The evidence gap identified suggests insufficient clinical trial data comparing drug efficacy specifically in psychotic depression. This knowledge void leaves clinicians without clear guidance for treating this severe condition with high morbidity and mortality risk.

Gap type: open_question Source paper: Pharmacological treatments for psychotic depression: a systematic review and network meta-analysis. (None, None, PMID:38360024)

Evidence summary

Resolved by hypothesis h-var-e2b5a7e7db: GluN2B-Mediated Thalamocortical Control of Glymphatic Tau Clearance. Score: 0.964. Supporting PMIDs: 19449329, 23431156, 26282667, 40994429, 40796363.